Displaying 1 - 20 of 119
| Active Ingredient | ANTIINFECTIVES |
| Therapeutic Class | ANTI-INFECTIVE AGENTS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ALBENDAZOLE |
| Therapeutic Class | ANTHELMINTICS |
| Indications | Threadworm, Whipworm, Roundworm, Strongyloides, Hookwormand Pinworm, neurocysticercosis |
| Caution | Gastrointestinal discomfort, headache. Do not use during pregnancy. Use an effective form of birth control while taking this medicine and for at least one month after your last dose. Patients being tr More ... |
| Dose Range | Adults and Children 2 years and over: 400mg as a single dose. Strongyloides: 400mg as a single dose for 3 consecutive days. Cutaneous Larva Migrans: 400mg daily for 3 days. Neurocysticercosis: 2 tablets twice daily for patients over 60kg. Under 60 |
| Drug Interactions | |
| Pregnancy | Avoid use in pregnancy. |
| Breast Feeding |
| Active Ingredient | LEVAMISOLE |
| Therapeutic Class | ANTHELMINTICS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | MEBENDAZOLE |
| Therapeutic Class | ANTHELMINTICS |
| Indications | Threadworm, roundworm, hookworm and whipworm |
| Caution | Cramps and diarrhoea, rash, headache. Avoid in pregnancy and in infants. Pyrexia, constipation, headache, dizziness, itching, swelling of face or mouth. Tablets may be chewed, swallowed or crus More ... |
| Dose Range | Adult and children 2 years and over: Threadworm 100mg as a single dose. Repeat regimen in 3 weeks if necessary. Whip worm, roundworm, hookworm 100mg twice daily for 3 consecutive days. |
| Drug Interactions | |
| Pregnancy | Avoid use in pregnancy. |
| Breast Feeding | Amount present in milk too small to be harmful but manufacturer advises avoid. |
| Active Ingredient | AMANTADINE |
| Therapeutic Class | ADAMANTANES |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ANTIRETROVIRALS |
| Therapeutic Class | ANTIRETROVIRALS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ATAZANAVIR |
| Therapeutic Class | HIV PROTEASE INHIBITORS |
| Indications | HIV-1 infection in treatment -naïve and treatment-experienced adults and pediatric patients 6 years of age or older. |
| Caution | Rash, abdominal pain, diarrhoea, nausea, unconjugated hyper- bilirubinemia, headache, lactic acidosis. |
| Dose Range | Adult: Atazanavir 300mg/ ritonavir 100mg once daily with food. |
| Drug Interactions | |
| Pregnancy | Theoretical risk of hyperbilirubinaemia in neonate if used at term. |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | DARUNAVIR |
| Therapeutic Class | HIV PROTEASE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | RITONAVIR |
| Therapeutic Class | HIV PROTEASE INHIBITORS |
| Indications |
Not typically used as sole protease inhibitor (PI), but as pharmacokinetic enhancer of other PIs Indicated in combination with other antiretroviral agents for the treatment of HIV-infection See lopin More ... |
| Caution | See lopinavir/ritonavir.Increased triglycerides, Diarrhea, Nausea , taste perversion, |
| Dose Range |
Initial dose 300mg twice daily gradually increased by 100mg twice daily over a period of up to 14 days to a maximum of 600mg twice daily . |
| Drug Interactions | |
| Pregnancy | See lopinavir/ritonavir. |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | SAQUINAVIR |
| Therapeutic Class | HIV PROTEASE INHIBITORS |
| Indications | Treatment of HIV infection in combination with ritonavir and other antiretroviral agents. |
| Caution | Diarrhea, abdominal discomfort. |
| Dose Range | Adults and children (16 yrs of age and older): 1g twice daily with ritonavir 100mg twice daily , or with lop inavir 400mg/ritonavir 100mg twice daily . Administer within 2 hours after a meal. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | DOLUTEGRAVIR |
| Therapeutic Class | INTEGRASE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ELVITEGRAVIR |
| Therapeutic Class | INTEGRASE INHIBITORS |
| Indications | The fixed combination of elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (tenofovir DF) (EVG/c/FTC/TDF) is used for the treatment of human immunodeficiency virus type 1 (HIV More ... |
| Caution | Lactic acidosis and hepatomegaly with steatosis, including fatalities, have been reported with Tenofovir DF in combination with other antiretrovirals; risk is increased in women, obese patients, prolo More ... |
| Dose Range | Elvitegravir is often given with a protease inhibitor, a pharmacokinetic enhancer such as low-dose ritonavir, and at least one other antiretroviral drug; the dose may need to be adjusted to manage drug interactions. |
| Drug Interactions |
Drugs that induce these enzymes may decrease its plasma concentration and it should not be used with strong inducers of CYP3A which include the following: antibacterials (rifampicin) antidepressants More ... |
| Pregnancy | There are no or limited amount of data (less than 300 pregnancy outcomes) from t More ... |
| Breast Feeding | In order to avoid transmission of HIV to the infant it is recommended that HIV i More ... |
| Active Ingredient | RALTEGRAVIR |
| Therapeutic Class | INTEGRASE INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | EFAVIRENZ |
| Therapeutic Class | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIB (NNRTI) |
| Indications |
In combination with other antiretrovirals for the treatment of HIV-1 infection. Efavirenz usually is used in HIV nonnucleoside reverse transcriptase inhibitor-based (NNRTI-based) regimens that includ More ... |
| Caution | Psychiatric disorders, rash, increases in liver enzymes. |
| Dose Range |
Adult: 600mg once daily on an empty stomach preferably at bedtime. Pediatric: 3 years and older and weighing between 10-40kg: 200mg-600mg once daily . |
| Drug Interactions | Efavirenz induces CYP3A and 2B6, and may alter plasma concentrations of drugs metabolized by these enzymes. |
| Pregnancy | Efavirenz may cause fetal harm if administered during the first trimester of pre More ... |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | NEVIRAPINE |
| Therapeutic Class | NNRTI |
| Indications | For use in combination with other antiretroviral agents for the treatment of HIV-1 infection. Nevirap ine reduces maternal to fetal HIV transmission. |
| Caution | Nevirapine is generally well-tolerated. The primary adverse effects are fever, nausea, and headache. However severe and life-threatening skin reactions, toxic epidermal necroly sis and Stevens-Johnson More ... |
| Dose Range | Adult: 200mg once daily for 14 day s, then increased to 200mg twice daily , in ombination with a nucleoside analogue antiretroviral agent. Pediatric: 2 months to 8 y ears: 4mg/kg/day for the first 14 day s followed by 7mg/kg twice daily . 8 y ea |
| Drug Interactions | |
| Pregnancy | The human pregnancy data for nevirapine suggest that the risk for embryo–fetal h More ... |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | ABACAVIR |
| Therapeutic Class | NRTI |
| Indications |
Indicated in combination with other anti-HIV medications for the treatment of HIV-1 for adults and children. |
| Caution | Nausea, vomiting, fatigue, headache, diarrhoea and loss of appetite. Fatal lactic acidosis and severe hep atomegaly with steatosis have been reported. Fatal hypersensitivity reactions include s More ... |
| Dose Range | Adult: Recommended dosing is 300mg orally twice daily with or without food. Pediatric: 3 months - 16 years of age is 8mg/kg orally twice daily (up to a maximum of 300mg twice daily ). Abacavir should be used in combination with other antiretrovirals. |
| Drug Interactions | Alcohol reduces the metabolism of abacavir. |
| Pregnancy | The animal data suggest moderate risk. Although the human pregnancy experience d More ... |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | DIDANOSINE |
| Therapeutic Class | NRTI |
| Indications | A first-line component of a combination antiretroviral therapy regimenfor HIV-1 infected p atients. |
| Caution | Diarrhoea, neuropathy , chills or fever, rash, abdominal pain,weakness, headache and nausea/vomiting. Serious toxicities have included pancreatitis and lactic acidosis (which may be fata More ... |
| Dose Range | Adult: weighing greater than 60kg, 200mg twice daily . Weighing less than or equal to 60kg, 125mg twice daily . Pediatric 8 months and older: 120mg/square meter twice daily . 2 weeks - 8 months: 100mg/square meter twice daily . Take on an empty stomach. |
| Drug Interactions | Coadministration of Didanosine and allopurinol is contraindicated because systemic exposures of Didanosine are increased, which may increase Didanosine-associated toxicity |
| Pregnancy | Reproduction studies have been performed in rats and rabbits at doses up to 12 a More ... |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | LAMIVUDINE |
| Therapeutic Class | NRTI |
| Indications | A combination of oral lamivudine and oral zidovudine has p roduced significant and sustained increases in CD4+ counts and decreases in viral load in HIV-infected patients. Lamivudine is indicated for More ... |
| Caution | Diarrhoea, headache, fatigue, insomnia, arthralgias, myalgias, neuropathy, nasal signs and symptoms, elevated liver enzymes, skin rash, fever or chills, ear, nose and throat infections. Concurrent use More ... |
| Dose Range |
Adult: 150mg orally twice daily , or 300mg once daily . Pediatric 3 months - 16 years: 4mg/kg twice daily (up to a maximum dose of 150mg twice a day ). Chronic hep atitis B: 100mg orally daily for adults and 3mg/kg once daily (maximum daily dose = |
| Drug Interactions | |
| Pregnancy | The animal and human data suggest that lamivudine is a low risk to the developin More ... |
| Breast Feeding | Lamivudine is distributed into milk in humans. It is not known whether the drug More ... |
| Active Ingredient | STAVUDINE |
| Therapeutic Class | NRTI |
| Indications | Adult and Children 12 years and over: One tablet twice daily (150mg lamivudine/300mg zidovudine p er tablet). Not recommended in children under 12 y ears. |
| Caution | Peripheral neuropathy , serum transaminase elevations, lactic acidosis and severe hepatomegaly with steatosis including fatal cases have been reported. Concurrent administration of stavudine an More ... |
| Dose Range |
Adult greater than 60kg: 40mg every 12 hours and less than 60kg: 30mg every 12 hours. Pediatric: birth to 13 days: 0.5 mg/kg every 12 hours. 14 days and older: 1 mg/kg every 12 hours and weighing less than 30 kg. May be taken without regard to meals. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | ZIDOVUDINE |
| Therapeutic Class | NRTI |
| Indications | In combination with other antiretroviral agents for the treatment of HIV infection. Zidovudine is also indicated for the prevention of maternal to fetal HIV transmission during gestation, la More ... |
| Caution | Bone marrow suppression (anemia and/or neutropenia), nausea, vomiting, anorexia, headache, malaise, asthenia and insomnia occur. Concurrent use of zidovudine and alpha-interferon, dapsone, vincrist More ... |
| Dose Range | Adult: 600mg daily in divided doses in combination with other antiretroviral agents. Pediatric: 6 weeks to 12 years: 160mg/square meter orally every 8 hours (maximum dose, 200 mg every 8 hours) in combination with other antiretroviral agents. To prevent |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |